Evidence map›Paper›PMID 29198136›Full record

ArticleASN neuro

Hyperhomocysteinemia-Induced Gene Expression Changes in the Cell Types of the Brain.

Erica M Weekman, Abigail E Woolums, Tiffany L Sudduth, Donna M Wilcock

Open access · goldAbstract read
In one paragraph

Article in ASN neuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Apolipoprotein E ε4/4 genotype limits response to dietary induction of hyperhomocysteinemia and resulting inflammatory signaling.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Article
  8. Article
  9. Relationships of Serum Homocysteine, Vitamin BBioMed research international · 2022
    Article
  10. Homocysteine fibrillar assemblies display cross-talk with Alzheimer's disease β-amyloid polypeptide.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Homocysteine and Gliotoxicity.Neurotoxicity research · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Hyperhomocysteinemia: Clinical Insights.Journal of central nervous system disease · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erica M Weekman1 Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
Abigail E Woolums1 Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
Tiffany L Sudduth1 Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
Donna M Wilcock1 Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
University of Kentucky · US

Funding

Neurovascular astrocyte dysfunction in VCIDR01NS097722 · NINDS · UNIVERSITY OF KENTUCKY · PI WILCOCK, DONNA M · 2017 to 2021
$2.1M
Vascular breakdown in Alzheimers Disease with cerebrovascular diseaseR01NS079637 · NINDS · UNIVERSITY OF KENTUCKY · PI WILCOCK, DONNA M · 2012 to 2016
$1.6M
NINDS NIH HHS R01 NS079637NINDS NIH HHS R01 NS097722
6 · The paper itself

Abstract

High plasma levels of homocysteine, termed hyperhomocysteinemia, are a risk factor for vascular cognitive impairment and dementia, which is the second leading cause of dementia. While hyperhomocysteinemia induces microhemorrhages and cognitive decline in mice, the specific effect of hyperhomocysteinemia on each cell type remains unknown. We took separate cultures of astrocytes, microglia, endothelial cells, and neuronal cells and treated each with moderate levels of homocysteine for 24, 48, 72, and 96 hr. We then determined the gene expression changes for cell-specific markers and neuroinflammatory markers including the matrix metalloproteinase 9 system. Astrocytes had decreased levels of several astrocytic end feet genes, such as aquaporin 4 and an adenosine triphosphate (ATP)-sensitive inward rectifier potassium channel at 72 hr, as well as an increase in matrix metalloproteinase 9 at 48 hr. Gene changes in microglia indicated a peak in proinflammatory markers at 48 hr followed by a peak in the anti-inflammatory marker, interleukin 1 receptor antagonist, at 72 hr. Endothelial cells had reduced occludin expression at 72 hr, while kinases and phosphatases known to alter tau phosphorylation states were increased in neuronal cells. This suggests that hyperhomocysteinemia induces early proinflammatory changes in microglia and astrocytic changes relevant to their interaction with the vasculature. Overall, the data show how hyperhomocysteinemia could impact Alzheimer's disease and vascular cognitive impairment and dementia.

Indexed as

Adenosine TriphosphateAnimalsBrainCytokinesDose-Response Relationship, DrugEndothelial CellsGene ExpressionHomocysteineHyperhomocysteinemiaMatrix Metalloproteinase 9MiceMice, Inbred C57BLNeurogliaNeuronsOccludinRNA, MessengerAdenosine TriphosphateCytokinesHomocysteineMatrix Metalloproteinase 9OccludinRNA, Messengerhyperhomocysteinemiamatrix metalloproteinaseneuroinflammationvascular cognitive impairment and dementia

Identifiers

PMID29198136
PMCPMC5718317
OpenAlexW2773896948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.